The Recall Desk
Agency classClass IOur severity:SevereFDA (Devices)·Z-0316-2027·Announced 2026-11-11

Tandem Mobi Insulin Pumps Recalled for False Occlusion Alarms

Tandem Diabetes Care is recalling Mobi insulin pumps that may generate false occlusion alarms, potentially interrupting insulin delivery and increasing the risk of elevated blood glucose.

The agency’s classification

FDA (Devices): Class I

Class I is a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.

This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work

What this means for you

Our assessment, not the agency’s: severity 4/5 (Severe).

The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: The recall is classified as FDA Class I because the false-positive occlusion alarms can interrupt insulin delivery, leading to hyperglycemia that may require medical intervention or hospitalization. The source does not report any specific illnesses, injuries, or deaths.

Plain-English summary

Tandem Diabetes Care, Inc. is recalling certain Tandem Mobi insulin pumps because they may generate false-positive occlusion alarms when no actual insulin flow obstruction is present. The investigation determined that increased friction within the drive module can reduce available motor power, causing the motor speed to fall below the occlusion detection threshold under certain conditions. This leads the pump to incorrectly detect an occlusion and suspend insulin delivery.

When these false alarms occur, insulin delivery remains suspended until the user acknowledges the alarm and resumes therapy. Repeated false-positive occlusion alarms that are not addressed promptly may result in interruptions of insulin delivery, which can increase the risk of elevated blood glucose levels. In severe cases, the resulting hyperglycemia may require medical intervention or hospitalization.

The recall affects 80,938 units, including 77,559 in the United States and 3,379 outside the US. The affected pumps were distributed nationwide in the US and in Canada. Consumers should check their pump serial numbers against the list provided by the manufacturer and follow instructions for exchange if their device is affected.

The recalled product

Product
Tandem Mobi Insulin Pump, Models: 1004004, 1010750, 1012676, 1012719, 1013655, 1013656, 1013501, 1013700, 1014081, 1014801, 1014811, 1014813, 1014936, 1016911, 1016912, 1016913, 1016914, 1018075, 1018077, 1018078

Distribution

Distributed nationwide across the United States.

The notice also names 52 states specifically: